✦ LIBER ✦

17 Use of Gefitinib (Iressa) in patients with EGFR positive NSCLC in the Pan Birmingham Cancer Network

✍ Scribed by Plant, R.; Chetiyawardana, S.; Thompson, J.; Williams, S.; Ghafoor, Q.

Book ID: 118574958
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 43 KB
Volume: 75
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(12)70018-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN7 THE LIFETIME COST OF GEFITINIB (“IR

PCN7 THE LIFETIME COST OF GEFITINIB (“IRESSA”) IN TREATING PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)

✍ A Haiderali; W Chin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

25 Gefitinib in the treatment of non-sma

25 Gefitinib in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-TK mutation – North Trent Cancer Network experience

✍ Nugent, L.; Das, T.; Mohanamurali, J.; Danson, S.J.; Fisher, P.M.; Hatton, M.Q.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 43 KB

P-449 FDG-PET SCAN in the evaluation of

P-449 FDG-PET SCAN in the evaluation of gefitinib (Iressa®) for patients with non-small cell lung cancer (NSCLC)

✍ Miwa, Toshiro; Kashii, Tatsuhiko; Oda, Hirofumi; Fujita, Tadashi; Fujishita, Tak 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 176 KB

Three Years of the Gefitinib UK Single P

Three Years of the Gefitinib UK Single Patient Access (SPA) Scheme: Duration of Treatment for Patients with EGFR Mutation Positive NSCLC in NHS Clinical Practice

✍ Vioix, H.; Franzen, S.; Selby, D.; Collomb, D.; Hauch, O.; Emmas, C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

OP78 EGFR mutations based on circulating

OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)

✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Usefulness of EGFR mutation screening in

Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer

✍ Junichi Soh; Shinichi Toyooka; Keisuke Aoe; Hiroaki Asano; Syuji Ichihara; Hidek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 467 KB 👁 2 views

## Abstract The importance of epidermal growth factor receptor (EGFR) gene mutation has been recognized in nonsmall cell lung cancer (NSCLC), requiring the standardization of mutation screening system including the kind of samples. Here, we examined the __EGFR__ mutation status in 61 pleural fluid